PEN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Penumbra Inc. is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company's financial performance is solid and analysts have generally positive ratings, the pending acquisition by Boston Scientific introduces uncertainty, and insider selling is a notable negative signal. Additionally, the lack of strong proprietary trading signals and neutral technical indicators suggest waiting for clearer entry points.
The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 47.837, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support is at 338.479, and resistance is at 343.537, with the current price near the pivot level of 341.008. Overall, the technical indicators are mixed, leaning slightly neutral.
The company's Q4 2025 financials showed strong growth with revenue up 22.14% YoY, net income up 40.55% YoY, and EPS up 46.34% YoY. Analysts have raised price targets, citing strong U.S. Embo growth and potential catalysts in 2026, such as Thunderbolt approval and sector recovery.
The pending acquisition by Boston Scientific creates uncertainty, and insider selling has increased significantly (617.99% over the last month). Additionally, hedge funds remain neutral, and there are no significant trading trends. The stock also faces potential headwinds from delayed Thunderbolt approval and missed U.S. Thrombectomy targets.
In Q4 2025, Penumbra reported strong financial growth. Revenue increased to $385.39M (up 22.14% YoY), net income rose to $47.34M (up 40.55% YoY), EPS grew to 1.2 (up 46.34% YoY), and gross margin improved to 68.02% (up 1.84% YoY).
Analysts have mixed ratings. While Evercore ISI and others maintain Outperform ratings with raised price targets (e.g., $360 from $340), Truist and Baird downgraded the stock to Neutral or Hold due to the pending acquisition. Analysts generally see 2026 as a positive year for MedTech, but the acquisition limits upside potential in the short term.
